Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that patients with rheumatoid arthritis, atopic dermatitis, and alopecia areata receiving baricitinib had low incidence rates of adverse events, especially among low-risk individuals, with varying rates among those at higher risk.

This study identified 11 previously unreported ABCA12 variants associated with varying severities of autosomal recessive congenital ichthyoses and expanded the phenotype spectrum of ichthyosis linked to these variants.

In this study, dutasteride treatment in retinitis pigmentosa mice increased photoreceptor survival and reduced glial activation, suggesting it may offer a neuroprotective effect.

This study evaluated hair tonic and gel formulations containing Angiopteris evecta root water extract and found both fulfilled pharmaceutical preparation standards, with the 12.5% hair tonic and 10.0% gel concentrations most effective for hair growth without a significant difference in performance.

This study examined phase 3 clinical trial data and found that baricitinib improves hair regrowth in adults with alopecia areata and significant scalp hair loss, with the response varying based on the severity of hair loss at the start of treatment.

This review assessed randomised clinical trials on the efficacy and safety of topical and systemic JAK inhibitors for alopecia areata, finding significant hair coverage improvement with ritlecitinibe and baricitinibe, though prolonged treatment is often needed to maintain results.

This study found that using nanoporous silica entrapped lipid-drug complexes enhanced the solubility and bioavailability of dutasteride in beagle dogs.

This study found that a single ablative fractional laser treatment significantly reduced hedgehog pathway gene expression in microscopic murine basal cell carcinomas, nearly matching the effects of repeated topical vismodegib applications.

In this study, researchers found that microinfusion of dutasteride using the MMP® technique did not show a statistical difference compared to placebo in clinical assessments for male androgenetic alopecia, though patients reported improvements in the vertex area.

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

This study reports that Elvitegravir, a drug currently approved for other uses, shows potential as a neuro- and mitoprotective agent by attenuating mitochondrial damage caused by NMDA receptors in primary mouse cortical neurons.

This review discusses adrenal gland disease in ferrets, exploring its signs, potential contributing factors, and current treatment options, but it reports no new clinical results.

The authors concluded that finasteride should be preferred over dutasteride for treating male androgenetic alopecia, as it better preserves certain important functions.

In this case report, treatment involving anthelmintic pyrantel pamoate and antiparasitic sarolaner effectively reduced pruritus and physical symptoms of scabiosis and ancylostomyosis in a puppy, with notable improvements observed by day 14.

A man developed a rare blood vessel connection on his scalp after hair transplants, which was successfully treated with surgery.

In this veterinary case report, the treatment of a 3-year-old male cat named Chipmunk for scabiosis, otitis externa, toxocariosis, and ancylostomiasis using ivermectin, diphenhydramine, drontal, and additional medications was found to be clinically effective.

This review highlights recent progress in developing androgen receptor degraders, such as PROTACs, for treating castration-resistant prostate cancer, and notes that several have entered phase I or II clinical trials, showcasing potential to address drug resistance challenges.

In this study on wound healing, sulfated glycosaminoglycans from sturgeon cartilage enhanced fibroblast cell proliferation, migration, and collagen deposition, significantly accelerating wound closure and promoting re-epithelialization in both in vitro and in vivo tests.

In this study, adults with severe alopecia areata experienced greater improvements in hair regrowth, health-related quality of life, and reduced anxiety and depression symptoms after 36 weeks of treatment with baricitinib compared to placebo.

This case study from Ukraine describes a 5-year-old Akita dog diagnosed with sebaceous adenitis, presenting with pruritus, alopecia, and inflammation; treatment over 30 days led to complete restoration of affected areas, implicating potential heritability in Akitas.

Finasteride and dutasteride may cause macular abnormalities.

This study found that inhibiting the ATR kinase with VE-822 impairs DNA repair capability in quiescent human keratinocytes exposed to solar-simulated UV radiation, suggesting ATR's critical role in facilitating effective DNA damage repair and cellular recovery under UV stress conditions.

In this study, researchers observed that after 5 years of treatment, 89.9% of Korean men with androgenetic alopecia experienced improvement and 93.9% had prevention of disease progression with dutasteride 0.5mg, though sexual-related symptoms were common early but subsided over time.

In this study, researchers propose that different vertebrate skin appendages, such as hair, feathers, and scales, evolved in parallel from a shared ancestral cell structure associated with teeth, dating back approximately 420 million years ago.

This study found that dutasteride significantly reduces the risk of acute urinary retention and surgical intervention in men with benign prostatic enlargement compared to placebo.

In this study, ALRV5XR treatment significantly increased terminal hair density in men with androgenetic alopecia after 24 weeks, while also decreasing vellus hair density, and was well tolerated without adverse events, suggesting its potential efficacy over standard therapies.

This study found that an injectable calcium alginate-amelogenin hydrogel is biocompatible, degradable, anti-inflammatory, and promotes osteogenesis, which may enhance the bone healing process in jaw and facial bone defect areas by mediating the bone immune microenvironment.

This study found that a synthetic avicequinone C analogue, 5e, was significantly more potent in inhibiting steroid 5α-reductase type 1 activity in human keratinocytes compared to the original isolated compound.